Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
In a study of 91 adolescents, average weight loss was
In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Average weight reduction was
Obesity among adolescents is a growing concern. According to the World Health Organization, worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled.1 These trends are particularly concerning as living with obesity in childhood or adolescence can lead to obesity-related complications in adulthood.2,3 Prior research has shown that while bariatric surgical procedures have become a more common treatment in adults living with obesity, patients, families, and providers are hesitant about the use of these invasive procedures in adolescents.4 In addition, earlier this year, the United States Preventive Services Task Force concluded that the evidence for the use of pharmacotherapy—including GLP-1 drugs—was inadequate in children and adolescents.5 This study affirms Allurion's belief that the Allurion Balloon represents a novel, non-invasive, safe, and effective treatment option for adolescents which can allow for earlier intervention in the treatment of obesity.
“Bariatric surgery and long-term pharmacotherapy, although effective in adults, raises concerns about invasiveness and potential risks when applied to adolescents,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe that the results of this study mark a significant milestone in the treatment of adolescent obesity, as the Allurion Balloon offers a non-invasive treatment option without several of the issues related to surgery and medications.”
Sources: 1. World Health Organization 2. Singh et al. Obes Rev. 2008;9(5):474-88. 3. Hassapidou et al. Obesity Facts. 2023;16(1):29-52. 4. Thenappan and Nadler. Current Gastroenterology Reports. 2019;21(6). 5. US Preventive Services Task Force. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226–232.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905867687/en/
Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investor
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Source: Allurion Technologies, Inc.